![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » OSCIENT PHARMACEUTICALS CORPORATION AND ABBOTT CANADA ENTER INTO COMMERCIALIZATION AGREEMENT FOR FACTIVE TABLETS
OSCIENT PHARMACEUTICALS CORPORATION AND ABBOTT CANADA ENTER INTO COMMERCIALIZATION AGREEMENT FOR FACTIVE TABLETS
August 10, 2006
Oscient Pharmaceuticals Corporation has granted the commercialization rights to FACTIVE (gemifloxacin mesylate) tablets in Canada to Abbott Canada, the Canadian affiliate of Abbott. In exchange for those rights, Abbott Canada has agreed to a transfer price on product purchases and to make certain payments to Oscient
upon achievement of certain regulatory and sales milestones. Specific financial
terms were not disclosed.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct